Please login to the form below

Not currently logged in
Email:
Password:

Former AstraZeneca man Graham Walker joins Idea Pharma

Will work with product teams to bridge gap between clinical and commercial

Graham Walker - IDEA PharmaDr Graham Walker has joined product design consultants Idea Pharma as a member of its Ideation team.

He will work alongside global product teams to form strategies for compounds in phase II development in an attempt to link more closely the clinical and commercial stages of a drug's lifespan.

Dr Walker's previous experience in the field includes two years at AstraZeneca between 2009 and 2010 where he served as therapy area physician - oncology.

During his time at the pharma company he was part of the team that helped bring the non small cell lung cancer (NSCLC) drug Iressa (gefitinib) to market.

Dr Walker later left AZ to join Napp Pharmacueuticals in the UK where he worked on the company's respiratory products.

Prior to his career in the industry, Dr Walker served in the clinical environment at several UK hospitals.

He was also director of his own technology company, HealthTrade, from 2001 to 2008, which used the latest technological advancements to provide healthcare solutions.

“My career to date has been built on spearheading innovation within many commercial organisations,” said Dr Walker, “so it makes complete sense to join Idea, a company that is clearly leading the industry in ensuring innovative drugs get to market in great shape. I look forward to tackling the challenges that lie ahead.”

Mike Rea, Idea's CEO, commented: “We were really lucky to find Graham. He was about to accept a great position with one of the 'top 5' when we met.”

14th May 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics